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Introduction/Objective: Acquired tracheal stenosis (ATS) is an unusual disease 
often secondary to prolonged mechanical trauma. ATS pathogenesis involves 
inflammation and subsequent fibrosis with narrowing of the tracheal lumen. TGF-β 
represents a pivotal factor in most fibrotic processes and therefore, a potential target 
in this context. The aim of this study is to analyze the role of TGF-β as a target for 
anti-fibrotic interventions in tracheal stenosis.  
Methods: Human stenotic tracheobronchial tissues from patients with benign airway 
stenosis and normal controls from pneumonectomy specimens were analyzed. 
Tracheal stenosis was induced in adult NZ rabbits by a circumferential thermal injury 
to the mucosa during open surgery and re-anastomosis. Rabbits were treated 
postoperatively with a peritracheal collagen sponge containing a TGF-β peptide 
antagonist (p17) or vehicle. Fibrosis was determined by Masson’s trichrome staining, 
and α-SMA+
Results: Human and rabbit stenotic tissues showed extensive submucosal fibrosis, 
characterized by significantly increased α-SMA
 myofibroblasts, CTGF and p-Smad2/3 expression by 
immunohistochemistry.  
+ myofibroblasts and CTGF 
expression. In human stenotic lesions, increased p-Smad2/3+ nuclei were also 
observed. p17 treatment significantly reduced the fibrotic thickness as well as the 
density of α-SMA+ myofibroblasts and CTGF+
Conclusion: ATS is characterized by a TGF-β dependent fibrotic process but 
reduction of the fibrotic component by TGF-β1 antagonist therapy was not sufficient 
to improve tracheal narrowing, suggesting that fibrosis may not be the main 
contributor to luminal stenosis. 
 cells in rabbit stenotic lesions but failed 
to improve the luminal area.  
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Introduction 
   Acquired tracheal stenosis (ATS) is an unusual disease which main causes are 
related to mechanical stress by endotracheal intubation or tracheostomy tubes. 
Burns, trauma, previous surgery, and infectious or autoimmune inflammatory 
diseases may also be responsible for ATS1. Since the initial experience reported by 
McDonald and Stocks2 regarding extended endotracheal intubation as a way of 
ventilatory support in pre-term neonates, the incidence of airway stenosis in children 
has increased substantially3. A long-standing cuffed endotracheal tube may cause 
mucosal damage and secondary scarring resulting in ATS. The histologic changes 
observed in the mucosa include inflammation, granulation tissue formation and 
fibrosis with subsequent narrowing of the tracheal lumen4
   The type of treatment to be instituted in a patient with ATS depends on the 
severity, morphologic type of the lesion, and the etiologic factors. An obstruction of 
50% or more of the tracheal lumen is definitely symptomatic and requires surgical or 
endoscopic therapy. In selected cases, tracheal resection of the stenosis with end to 
end anastomosis may offer a good and permanent result. Endoscopic procedures, 
such as balloon dilation, laser photoresection or stenting may be indicated in 
selected cases. Overall, treatment failure for both surgical and endoscopic treatment 
may vary between 9% and 43% in different studies, due to severe complications 




   The role of medical therapy is less clear. Local treatments with corticoids or 
mitomycin C have been empirically tried with variable results
. 
8,9. Therefore, the study 
of the specific factors involved in the development of granulation tissue and fibrosis 
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causing ATS may help to identify potential therapeutic targets. Although the precise 
pathomechanism is not known, a general response to injury or mechanical stress to 
the respiratory epithelium involves selective release of transforming growth factor-β1 
(TGF-β1)10, one of the key molecular factors involved in fibrogenesis11,12. Several 
cellular and molecular pathways such as M2 macrophage dysregulation or activation 
of the IL-17 axis may initiate the process leading to excessive fibroproliferative 
responses, an emerging target for intervention13,14,15
   TGF-β signals through specific receptors that trigger a specific intracellular 
signalling cascade, leading to phosphorylation and activation of SMAD proteins. 
pSmad2/3 form a heteromeric complex with Smad4 and translocate into nucleus 
where they act as specific transcription factors, initiating normal or pathological 
scarring responses
.  
16,17. Therefore pSMAD detection is a surrogate marker for TGF-β 
activation and response. TGF-β response involves differentiation of stromal cells into 
high extracellular matrix ECM-secreting myofibroblasts, characterized by smooth 
muscle cell α-actin (α-SMA) expression18,19. TGF-β also induces the expression of 
connective tissue growth factor (CTGF) gene, a cysteine-rich protein that further 
enhances the pro-fibrotic effects of TGF-β and that is expressed in most fibrotic 
conditions20-22. Therefore, TGF-β represents a potential therapeutic target in different 
fibrotic conditions. TGF-β antagonistic antibodies or peptides have shown anti-fibrotic 
activity in a variety of experimental models of fibrosis23-27
   Several animal models for ATS secondary to different types of trauma that 





. We aim to identify the participation of TGF-β signalling in 
the pathologic process of human and experimental ATS and to evaluate the capacity 
of a TGF-β peptide antagonist to reduce fibrosis and tracheal stenosis in an animal 
experimental model.  
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Materials and Methods 
Ethics statement 
All human and animal procedures were approved by Clinical Research Committee 
and Animal Care and Use Committee of Hospital 12 de Octubre with protocol 
reference number PI12/00646, and carried out in accordance with the institutional 
guidelines. 
Patients 
   Human tracheobronchial tissues were obtained by excision of stenotic lesions 
during elective therapeutic intervention of 7 pediatric or young adult patients with 
benign ATS (67% male and mean±SD age 20±7 years [11-28 years old]). Normal 
tracheobronchial tissues were obtained from 9 pulmonary resection specimens 
indicated by non-tracheal pathology (78% male and mean±SD age 63±4 years [58-
70 years old]).  
Animal model 
   We developed a model of tracheal stenosis in adult New Zealand White rabbits 
(Granja cunícola San Bernardo, Navarra, Spain). Briefly, an incomplete transverse 
incision of the trachea was performed under anaesthesia, followed by a 
circumferential thermal injury to the mucosa with electro-cauterization and suture. At 
4 weeks the tracheal segment was excised, fixed in formaldehyde 4% solution and 
paraffin embedded. In preliminary sequential studies from 2 to 12 weeks after the 
intervention, the maximal stenosis was observed in rabbits sacrificed at 4 weeks.  
   To determine the degree of stenosis, the luminal areas at the site of injury and at 
the first distal non-involved tracheal ring were photographed and the stenotic/normal 
luminal area ratio calculated using ImageJ software (http://rsb.info.nih.gov/ij). 
   For the intervention study, a total of forty rabbits were divided into two groups 
(saline and p17 treatment). In addition, a group of ten rabbits was used as control of 
the surgical procedure. 
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Histology and immunohistochemistry 
   Submucosal fibrosis was evaluated as the maximal thickening of the submucosal 
collagen stained tissue on Masson’s trichrome stained tracheal sections, which was 
measured using ImageJ software. Tracheas were also stained with Safranin O to 
assess biochemical and structural integrity of cartilage. 
   Immunohistochemistry (IHC) was performed on deparaffinised and rehydrated 
tissues, after microwave heating in 1mM EDTA pH8 for antigen retrieval. 
Immunoperoxidase labelling was performed with mouse monoclonal anti-α-SMA 
antibody (1A4 clone, Sigma-Aldrich Química, Madrid, Spain), rabbit polyclonal anti-
pSmad2/3 antibody and goat polyclonal L20 anti-CTGF antibodies (Santa Cruz 
Biotechnology, CA, USA) and developed by diaminobenzidine chromogen (Vector 
Laboratories, Burlingame, CA, USA). Rabbit and human tissues were stained with α-
SMA and CTGF antibodies whereas pSmad2/3 antibody could only specifically 
recognize pSmad2/3 in human tracheal sections. 
   Immunostained sections were visualized on a Zeiss Scope.A1 microscope (Zeiss, 
Jena, Germany), photographed and digitalized using an AxioCam ERc 5S camera 
and ZEN lite 2012 software. The number of α-SMA and CTGF positive cells per area 
were determined. 
Local treatment with p17 TGF-β antagonist 
   To confirm the involvement of TGF-β in the rabbit experimental model of tracheal 
stenosis, a peritracheal collagen sponge containing a peptide antagonist of TGF-β 
p17 (2mg/ml) or control vehicle (0.9% saline) was sutured around the trachea after 
anastomosis. p17 is a soluble hydrophilic peptide derived from a phage display 
peptide library. It is capable of blocking the effects of TGF-β1 both in vitro and in vivo 
and has demonstrated anti-fibrotic activity across different species24,31-36. Four weeks 
after the surgical procedure, rabbits were sacrificed and tracheas were excised and 




   Statistical differences were analyzed using Prism software v6.0 (GraphPad 
Software, San Diego, CA, USA). Quantitative data were analyzed by Mann–Whitney 
U-test and correlation analysis by Spearman’s rank test. P values less than 0.05 
were considered significant. 
Results 
Human tracheal stenotic tissue show features of TGF-β driven fibrosis 
   To analyze the histopathological changes in the tracheobronchial tissue of patients 
with benign airway stenosis, we compared stenotic specimens with normal control 
tracheobronchial tissues. Histological examination confirmed an extensive 
submucosal fibrotic component, with an enhanced collagen stained area, as well as 
a variable inflammatory cell infiltration and epithelial hyperplasia in all cases of 
tracheal stenosis (Fig. 1). 
   To obtain evidence of TGF-β participation in the human submucosal fibrotic 
lesions, we analyzed by IHC the expression of several surrogate markers of TGF-β 
signalling. We first compared the presence of nuclear phosphorylated Smad2/3 (p-
Smad2/3) in stenotic versus normal tracheobronchial tissues. In normal control 
tracheas, p-Smad2/3 positive nuclei were rarely observed, whereas in stenotic 
tissues a significant increase of p-Smad2/3 positive nuclei was observed in both 
tracheal epithelial and submucosal cells (Fig. 1). 
   The expression of the TGF-β inducible pro-fibrotic factor CTGF was also 
significantly increased in stenotic compared to normal tracheobronchial tissues. 
Whereas normal trachea showed minimal or absent CTGF immunostaining, an 
important increase in the number of CTGF expressing cells, most with stromal cell 
shape, in the submucosal fibrotic connective tissue (Fig. 1).  
   Finally, the presence of α-SMA+ myofibroblasts was analyzed. In normal 
tracheobronchial tissues, only vascular and smooth muscle structures showed α-
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SMA+ expression. In stenotic tissues, an abundant infiltrate by α-SMA+
The rabbit model of tracheal stenosis reproduces the human fibrotic process 
 cells with 
stromal shape consistent with myofibroblasts was observed in the submucosal 
fibrotic area (Fig. 1).  
   Rabbit tracheal tissues undergoing surgical procedure showed a progressive 
luminal stenosis from 2 to 4 weeks that tended to spontaneously decrease at 12 
weeks (Supp. Fig. S1).  Tracheal stenosis was histologically characterized by a 
prominent fibrotic response in the submucosa, with a significant thickened collagen 
stained area by Masson’s trichrome (Fig. 2). Safranin O staining showed cartilage 
damage in stenotic areas, as patchy areas of reduced cartilage thickness and 
weaker proteoglycan staining (Supp. Fig. S2). In addition, epithelial hyperplasia and 
an abundant inflammatory infiltrate, mainly composed by mononuclear and mast 
cells, were evident in the stenotic lesion (Fig. 2). A significant increase in the number 
of α-SMA+ myofibroblasts and CTGF+
Effect of TGF-β antagonist on experimental tracheal stenosis 
 cells per area were also observed in stromal 
cells of stenotic tracheal tissues compared to control group (Fig. 2). 
   To evaluate the potential contribution of TGF-β to the development of submucosal 
fibrosis and tracheal stenosis, rabbits were treated with peri-tracheal collagen 
sponges containing the TGF-β inhibitor p17 peptide or vehicle control. Thirty four of 
40 rabbits were analyzed at 4 weeks. The rest were excluded due to early mortality 
or signs of local infection. To quantify fibrosis, we measured the maximal thickness of 
the submucosal collagen stained area which was significantly reduced in p17 treated 
compared to saline treated group (Fig. 3). The densities of α-SMA+ myofibroblasts 
and CTGF+ cells per mm2
 
 were significantly reduced by p17 treatment (Fig. 3). Focal 
areas of reduced proteoglycan staining, and reduced cartilage thickness were 
similarly observed in p17 and control group (Supp. Fig. S2). 
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   The degree of luminal stenosis was evaluated in both groups of rabbits as the 
stenotic/normal luminal area ratio. Despite the observed reduction in fibrosis, we did 
not observe a significant increase in the luminal area in p17 compared to saline-
treated group (Fig. 4A and 4B). Since this data suggested that stenosis did not 
improve as much as the fibrotic component, we analysed the correlation between 
both variables, the collagen thickness and the luminal area. Although there was a 
trend to negative correlation between the luminal area and collagen thickness, the 
correlation coefficient was low (r=0.29) and non-significant (Fig. 4C). 
 
Discussion 
   The investigation of the mediators involved in the development of the granulation 
tissue and fibrotic response responsible for the development of ATS is relevant to the 
identification of targets of pharmacological therapies. Non-specific anti-inflammatory 
strategies such as glucocorticoids have shown a limited therapeutic impact5,37
   Previous studies have identified an important submucosal fibrotic component in 
stenotic lesions, that may be the end-result of the activation of specific inflammatory 
pathways
 and 
therefore, more specific therapeutic targets are needed. However, obtaining 
mechanistic information is being limited by human tissue availability and data from 
appropriate animal models are also scarce. 
13,14,15. However, the pathogenic relevance of common pro-fibrotic 
mediators such as the TGF-β pro-fibrotic pathway had not been addressed. 
Increased expression of TGF-β and VEGF in stenotic lesions has been described38-
40. TGF-β could be directly induced by mechanical pressure on the respiratory 
epithelium as suggested by data in cultured bronchial epithelial cells providing a link 
between mechanical stress and the inflammatory and stenotic response38
   Our data confirm that there is an important fibrotic component in tracheal stenotic 




and α-SMA). In addition, these features were reproduced in the animal model of 
tracheal stenosis. After the surgical procedure, rabbit tracheal tissues showed 
marked submucosal fibrosis accompanied by an increase CTGF expression and α-
SMA+
   We used a peptide antagonist of TGF-β that has demonstrated its ability to reduce 
fibrosis across different species, by interfering the binding of TGF-β to its receptors in 
vivo. p17 has shown potent anti-fibrotic effects by interfering TGFβ1 and β2 activity in 
a variety of animal models, either by systemic or local application
 myofibroblasts. Therefore, this animal model provides a valid preclinical to test 
the impact of TGF-β antagonist. 
24,26,27,34-36
   Our data provide consistent evidence on the role of TGF-β in the pathogenesis of 
tracheal fibrosis. p17 showed significant anti-fibrotic effects associated with a 
decreased expression of α-SMA and CTGF, two processes directly induced by TGF-
β. However, the significantly reduced accumulation of fibrotic tissue in tracheal 
submucosa was not accompanied by an improvement in the luminal tracheal 
stenosis. This suggests that other components such as inflammation, epithelial 
hyperplasia, or structural changes such as cartilage damage might contribute to the 
reduced tracheal lumen and remain unmodified despite anti-TGF-β effects on 
fibrosis. Indeed, we confirmed a poor and non-significant correlation between the 
degree of fibrosis and the tracheal luminal area in the rabbit experimental model. 
. Although 
local application by direct surgical implantation of collagen sponges containing p17 is 
not a feasible strategy to treat human stenosis, it guaranteed inhibitor availability in 
this proof of concept study. Since the release of active peptide to tracheal tissue is 
difficult to determine, a large excess of p17 was empirically used, considering data 
from previous local and systemic studies. We assume efficient delivery because it 
resulted into significant reduction of fibrosis but perhaps higher concentrations could 





   In summary, our data show evidence of the relevance of TGF-β in the 
pathogenesis of fibrosis in a human and an animal model of ATS but also an 
insufficient therapeutic effect of a TGF-β blocking strategy, suggesting that the 
fibrosis is only a partial contributor to the reduction of the tracheal lumen in ATS. 
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Fig. 1. Histopathological and immunohistochemical evaluation of human 
tracheal tissues. Representative images of Masson’s trichrome and quantitative 
analysis of p-Smad2/3, CTGF and α-SMA staining in control and stenotic tracheal 
tissues (Mean±SEM; *p<0.05, **p<0.01, ***p<0.001). Bar 100 µm in Masson’s and α-
SMA panels and 50 µm in p-Smad2/3 and CTGF panels. 
 
Fig. 2. Histopathological and immunohistochemical evaluation of experimental 
airway stenosis model in rabbits. Representative images of rabbit control and 
stenotic trachea at 4 weeks after thermal injury with 25x magnification and insets with 
200x magnification (Masson’s trichrome). Immunolabeling of α-SMA and CTGF 
positive cells in control and stenotic tracheal rings in an animal model of airway 
stenosis. Quantification of tracheal thicknening and α-SMA and CTGF positive cells 
per area (Data shown are mean±SEM; **p<0.01). Bars 400 µm (25x Masson’s 
panels) and 50 µm (Masson’s insets, α-SMA and CTGF staining).  
 
Fig. 3. Effect of p17 treatment on submucosal fibrosis and myofibroblasts and 
CTGF expression in rabbit experimental model. Rabbits were intraoperatively 
treated with p17 TGF-β antagonist or saline. Tracheal fibrosis was determined as the 
collagen area stained by Masson’s trichrome, and by the direct measure of tracheal 
thicknening (upper panel). Representative images and quantification of α-SMA 
(middle panel) and CTGF (lower panel) positive cells per area. Bar 100 µm, insets 
bar 25 µm. (Data shown are mean±SEM; **p<0.01, ***p<0.001).  
 
Fig. 4. Luminal stenosis in p17-treated rabbits. Representative images of saline-
treated and p17-treated tracheas (A). Cross-section of control (right) and stenotic 
(left) trachea. Quantitative analysis of tracheal luminal area in saline or p17 treated 
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rabbits (B). Correlation analysis between the luminal area and collagen thicknening 
(C). 
 
Supp. Fig. S1. Macroscopic analysis of rabbit tracheal sections undergoing 
surgical procedure.  Images show the area of maximal luminal stenosis (left rings) 
compared with the first distal uninvolved ring (right rings), at the indicated time points 
after surgery.  
 
Supp. Fig. S2. Evaluation of cartilage structure and proteoglycan staining in 
rabbit tracheal tissues. Representative images of cartilage damage determined by 
safranina O stained area in control (left), saline (middle) and p17-treated rabbits 
(right) are shown. Bar 100 µm. 






